● "Caring for women's bodies is caring for the planet." – Dr Helen O'Neill
● "The greatest global health challenge is inequity and ensuring people get access to care." – Professor Michael Kidd
● "Who is your user?" – Ida Tin
● "When creating tech, what's the purpose and endpoint?" – Dr Rebecca Lewis
As society inches closer to technological reform, healthcare becomes an increasingly interesting area to watch, from ethics to advances in genomic medicine.
At the Rhodes Forum on Technology & Society on 7 November 2026, themed "Human by Design: Technology, Agency, and the Futures We Choose", the plenary panel The Missing Half: Rethinking Women's Health brought together founders, clinicians and policymakers:
● Ida Tin, co-founder of the period-tracking app Clue, who coined the term "femtech"
● Dr Helen O'Neill, Associate Professor of Reproductive and Molecular Genetics at UCL's Institute for Women's Health, and founder and CEO of Hertility
● Dr Rebecca Lewis, GP, menopause specialist and co-founder of Newson Health
● Professor Michael Kidd AO, Chief Medical Officer for Australia
● Moderator: Dr Ragavi Jeyakumar (New South Wales & Balliol 2025)
Data and research funding
One of the core problems that recurred throughout the discussion was data. Ida Tin called hormone data the biggest gap in women's health. Hormones work like the body's operating system, she said, and it is inconceivable how little we know about them. As a result, she has tried to build and support continuous hormone monitoring to counter a healthcare system that is not tailored to women's bodies. Dr Helen O'Neill described the present landscape of health as a stalemate when one compares the advances made for men's and women's bodies. She went on to describe the structural issue of collecting hormone data at scale. Hormones fluctuate daily, so meaningful data requires sampling across the whole cycle. As it stands, hormones are at baseline on the third day of each cycle, which creates only 12 chances a year. According to Ida Tin, we have reached an inflection point in society where menopause is becoming a central topic in women's health, and while it is a long overdue conversation, it is still worth having.
The disparity in the quality of data can be partly explained by the way in which we collect data and where it comes from. Its biggest sources are clinical trials and pharmaceutical companies, and women have only been routinely included in clinical research for approximately 30 years. The implication of this is that decades of medical knowledge around how drugs are tested and dosed were built on studies of men, and yet women are still under-represented in the data. Hertility's women-first research has drawn on data from around 700,000 women over the past seven years, and for Dr O'Neill, building data like this is an opportunity to start again with ethics in mind and to build a foundation for solutions designed around women. Ultimately, she argued, it comes down to who gets to ask the questions and where we choose to invest in building capacity. Right now, there is a disconnect between female physiology and the problems we are trying to solve.
Dr Rebecca Lewis echoed these sentiments, pointing out that 60–70% of research is funded by pharmaceutical companies, which builds a bias into what gets funded. She called for increased mobilisation of government funds towards women and their health. However, there is an important caveat. Data alone is not enough, according to Dr Lewis. Research is not infallible and often won't give the complete answer, so patient values and lived experience need to be considered alongside the evidence. A further concern she raised was that as hormonal health becomes increasingly lucrative, "menowashing" is on the rise, with products such as menopause creams marketed to women without evidence to substantiate their benefits.
Representation, literacy and equity
Professor Michael Kidd opened by acknowledging his positionality as the only man on a women's health panel. Dr O'Neill responded that there is a need to involve men because women's health is societal infrastructure, and improving it cannot fall on women alone. For her, there should always be a man weighing in on these discussions. Professor Kidd also turned to who is shaping technology itself, highlighting that the men leading the tech industry have a huge impact on our day-to-day lives and our futures, without enough women alongside them.
The conversation leaned into advocacy and the significance of patients' health literacy. Dr Ragavi Jeyakumar and Professor Kidd pointed out that misinformation has rushed in to fill the gaps left by evidence-based medicine, while Dr Lewis highlighted wider knowledge gaps around postnatal mental health. Her message to women was that they are the experts on their own health: get informed, and if you are not being supported, ask to see someone else.
Dr Jeyakumar broadened the conversation by asking about people whose experiences and needs are often overlooked, including LGBTQ+ women and trans and non-binary people. Professor Kidd agreed, framing it as a question of equity. Inequity is the greatest challenge in global health, he said, and women's health is often where the cracks start to show. He talked about how multifaceted strategies to approach women's health need to be, from chronic disease and prevention to violence and mental health. Ultimately, he argued that a health system should be judged on whether every woman receives care that meets her needs.
Looking ahead
In their closing remarks, the panelists emphasised the need to build responsive systems of care and to ensure that the inequities of society are not embedded in the data, reproducing the same problems. While women's health has historically been under-resourced and underserved, it also presents an opportunity for progress. That starts with listening to women, investing in data that reflects their bodies, and designing care around everyone it is meant to serve. And this work belongs to all of us.